Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.96 |
| ▸ | HTR2A | P28223 | 1/20 | 0.77 |
| ▸ | HTR2C | P28335 | 1/20 | 0.77 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.74 |
| ▸ | NR2E1 | Q9Y466 | 2/20 | 0.74 |
| ▸ | HTR5A | P47898 | 1/20 | 0.74 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.74 |
| ▸ | PARP1 | P09874 | 1/20 | 0.65 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.55 |
| ▸ | RAD52 | P43351 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL169954 | 1.00 | TAAR1 (0.96) | TAAR1HTR2AHTR2CKDM4ENR2E1 | |
| Hydrochloric Acid SCHEMBL30741597 | 0.98 | TAAR1 (1.00) | TAAR1HTR2AHTR2CKDM4ENR2E1 | |
| Hydrochloric Acid SCHEMBL2243782 | 0.98 | TAAR1 (1.00) | TAAR1HTR2AHTR2CKDM4ENR2E1 | |
| SCHEMBL620253 | 0.89 | TAAR1 (0.78) | TAAR1HTR2AHTR2CKDM4ENR2E1 | |
| SCHEMBL3045846 | 0.87 | HTR2A (1.00) | TAAR1HTR2AHTR2CKDM4ENR2E1 | |
| SCHEMBL29736160 | 0.87 | HTR2A (1.00) | TAAR1HTR2AHTR2CKDM4ENR2E1 | |
| SCHEMBL2979137 | 0.86 | TAAR1 (0.73) | TAAR1HTR2AHTR2CKDM4ENR2E1 | |
| Tryptoline SCHEMBL12190178 | 0.85 | NISCH (1.00) | TAAR1HTR2AHTR2CKDM4ENR2E1 | |
| Tryptoline SCHEMBL171755 | 0.85 | NISCH (1.00) | TAAR1HTR2AHTR2CKDM4ENR2E1 | |
| Tryptoline SCHEMBL29350043 | 0.85 | NISCH (1.00) | TAAR1HTR2AHTR2CKDM4ENR2E1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118974060-A | Rifabutin analogs for treating diseases | 生物验证系统股份公司 | 2024-11-15 | — | — | CN | claimed |
| CN-115626889-B | Organic chemical conversion method for oxidative dehydrogenation of nitrogen-containing heterocyclic compound | 南京工业大学 | 2024-04-30 | — | — | CN | claimed |
| CN-115626889-A | Organic chemical conversion method for oxidative dehydrogenation of nitrogen-containing heterocyclic compound | 南京工业大学 | 2023-01-20 | — | — | CN | claimed |
| EP-4662217-A1 | RIFABUTIN ANALOGS FOR THE TREATMENT OF BACTERIAL DISEASES | BioVersys AG (CH) | 2025-12-17 | — | — | EP | disclosed |
| EP-4551251-A2 | CNS TARGETING COMPLEXES AND USES THEREOF | Dyne Therapeutics, Inc. (US) | 2025-05-14 | — | — | EP | disclosed |
| CN-119998299-A | Rifabutin analogs for treating diseases | 生物验证系统股份公司 | 2025-05-13 | — | — | CN | disclosed |
| US-20250145576-A1 | CATHEPSIN K INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | SHANDONG NEW TIME PHARMACEUTICAL CO., LTD. (CN) | 2025-05-08 | — | — | US | disclosed |
| EP-4508053-A1 | RIFABUTIN ANALOGS FOR THE TREATMENT OF DISEASE | BioVersys AG (CH) | 2025-02-19 | — | — | EP | disclosed |
| CN-119039396-A | Alkaline phosphatase-responsive self-assembled polypeptide capable of inducing in-situ degradation of CD47 protein, and preparation method and application thereof | 南开国际先进研究院(深圳福田) | 2024-11-29 | — | — | CN | disclosed |
| EP-4467544-A1 | CATHEPSIN K INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Shandong New Time Pharmaceutical Co., Ltd. (CN) | 2024-11-27 | — | — | EP | disclosed |
| CN-118974060-A | Rifabutin analogs for treating diseases | 生物验证系统股份公司 | 2024-11-15 | — | — | CN | disclosed |
| CN-115626889-B | Organic chemical conversion method for oxidative dehydrogenation of nitrogen-containing heterocyclic compound | 南京工业大学 | 2024-04-30 | — | — | CN | disclosed |
| WO-2024011150-A2 | CNS TARGETING COMPLEXES AND USES THEREOF | DYNE THERAPEUTICS, INC. (US) | 2024-01-11 | — | — | WO | disclosed |
| WO-2023198597-A1 | RIFABUTIN ANALOGS FOR THE TREATMENT OF DISEASE | BioVersys AG (CH) | 2023-10-19 | — | — | WO | disclosed |
| WO-2023118319-A1 | RIFABUTIN ANALOGS FOR THE TREATMENT OF DISEASE | BioVersys AG (CH) | 2023-06-29 | — | — | WO | disclosed |
| CN-113582947-B | Method for removing sulfonyl protection of amine | 南开大学 | 2023-06-20 | — | — | CN | disclosed |
| CN-115626889-A | Organic chemical conversion method for oxidative dehydrogenation of nitrogen-containing heterocyclic compound | 南京工业大学 | 2023-01-20 | — | — | CN | disclosed |
| JP-2022172130-A | 1,3,4,5-TETRAHYDRO-2H-PYRIDO(4,3-B)INDOLE DERIVATIVES FOR TREATMENT, ALLEVIATION OR PREVENTION OF DISORDERS ASSOCIATED WITH TAU AGGREGATES SUCH AS ALZHEIMER'S DISEASE | エーシー イミューン エス．エー． | 2022-11-15 | — | — | JP | disclosed |
| EP-3749293-B1 | 2,3,4,5-TETRAHYDRO-1H-PYRIDO[4, 3-B]INDOLE INHIBITORS OF CGAS FOR TREATING AUTOINFLAMMATORY DISEASES | UNIV ROCKEFELLER (US) | 2022-03-30 | — | — | EP | disclosed |
| EP-3749293-B1 | 2,3,4,5-TETRAHYDRO-1H-PYRIDO[4, 3-B]INDOLE INHIBITORS OF CGAS FOR TREATING AUTOINFLAMMATORY DISEASES | UNIV ROCKEFELLER (US) | 2022-03-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250145576-A1 | CATHEPSIN K INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | CTSF, CTSK, CTSZ | TAAR1 4608/4885HTR2A 4736/4885HTR2C 4522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.